Our scientific activities are supported in large parts by the German Research Foundation, the Federal Ministry of Education and Research and the Berlin Institue of Health, as well as by foundations and industry.

German Research Foundation

  • SFB/TR 84:
    „Innate Immunity of the Lung – Mechanisms of Pathogen Attack and Host Defence in Pneumonia“ 

    • Project C3: „Resolvins and other lipid mediators and their role in resolution of inflammation in pneumonia“ (in cooperation with Prof. K. Mayer, Gießen) – completed
    • Project C6: „The Angiopoietin-/Tie-2 system in severe pneumonia“ (in cooperation with Prof. N. Weissmann, Gießen)
    • Project C7: „Extracellular nucleic acids in serve pneumococcal pneumonia: Mechanisms and therapeutic approaches in combination with adrenomedullin“ (in cooperation with Dr. S. Fischer, Gießen) – completed
    • Project C9: „Role of CFTR and its downstream signaling in lung barrier failure in pneumonia“ (in Cooperation with Prof. W. Kübler and Prof. N Suttorp, Berlin)
  • SFB 1449:
    Dynamic Hydrogels at Biointerfaces“

    • Project B02: „Functional role of the alveolar epithelial glycocalyx in pulmonary defense and inflammation“ (in cooperation with P. Seeerger)
    • GRK1673: „Functional Molecular Infection Epidemiology“
      • „Impact of bacterial virulence factor variations and host molecule polymorphisms on activation of the host innate immune system in pneumococcal pneumonia“ (in Cooperation with Prof. Dr. B. Opitz, Berlin) – completed
    • Einzelantrag OP-76/1:

      „Role of the Caspase-1-Inflammasome in pneumococcal infection“ (in Cooperation with PD Dr. B. Opitz, Berlin) – completed


  • Mukoviszidose e.V. Bundesverband Cystische Fibrose
      • Disabling persistence and intrinsic resistance mechanism in Pseudomonas aeruginosa: learning from bacteria-phage interaction


  • Federal Ministry of Education and Research – BMBF
  • PROGRESS Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis
  • CAPSySSystems Medicine of Community Acquired Pneumonia
      • Subproject 4: „Experimental modelling and validation of pneumonia pathophysiology“
  • Phage4CureDeveloping bacteriophages as approved therapy against bacterial infections
  • SYMPATHSystem Medicine of Pneumonia-aggravated Atherosclerosis
  • MAPVAPPre-clinical mechanistic assessment of two bacteriophage cocktails targeting multidrug-resistant Pseudomonas aeruginosa and Escherichia coli for the treatment of ventilator-associated pneumonia
  • PROVID – Clinical, molecular and functional biomarkers for prognosis, pathomechanisms and treatment strategies of Covid-19
  • NAPKON the National Pandemics Cohort Network


  • Berlin Institute of Health – BIH
    • Pa-COVID-19
    • CM-COVID-19
    • Organospecific stratification of COVID-19

Industry and Foundations

  • VaxxilonVaccine innovation to prevent disease

  • Berlin Institute of Health
  • Biotest AG
  • Else Kröner-Fresenius Foundation
      • Research Grant 2012_A56: „The role of myeloid suppressor cells in secondary bacterial lung infections“

  • Jürgen Manchot Foundation
    (doctoral fellowships)
  • European Respiratory Society / EU Marie Skłodowska-Curie fellowship to Dr. Eleftheria Letsiou
  • Center of Infection Biology and Immunity (ZIBI)
  • CAPNETZ Foundation (material and data supply)
  • Bayer-Schering Pharma AG

  • Boehringer Ingelheim Pharma GmbH

  • NOXXON Pharma AG

  • Silence Therapeutics AG
  • Actelion Pharmaceuticals Ltd
  • Pari GmbH
  • others